ZYME
Zymeworks Inc.
Price Chart
Latest Quote
$24.04
-1.06 (-4.22%)
Current Price
| Previous Close | $25.10 |
| Open | $25.04 |
| Day High | $25.11 |
| Day Low | $24.02 |
| Volume | 458,160 |
Stock Information
| Shares Outstanding | 73.02M |
| Total Debt | $17.04M |
| Cash Equivalents | $364.73M |
| Revenue | $81.26M |
| Net Income | $-102.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.77B |
| EPS (TTM) | $-1.37 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.49B |
| Sales | $81.26M |
| Income | $-102.66M |
| Book/sh | $3.60 |
| Cash/sh | $4.99 |
| Employees | 243 |
Financial Ratios
| Quick Ratio | 10.36 |
| Current Ratio | 10.82 |
| Debt/Eq | 10.42 |
Returns & Margins
| ROA | -15.78% |
| ROE | -42.02% |
| Gross Margin | -67.01% |
| Operating Margin | -1956.73% |
| Profit Margin | -126.33% |
Ownership
| Insider Ownership | 1.27% |
| Institutional Ownership | 98.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 46.62 |
| P/S | 21.77 |
| P/B | 6.68 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $40.15 |
Technical Indicators
| SMA20 | $24.58 |
| SMA50 | $25.92 |
| SMA200 | $22.43 |
| RSI | 50.82 |
| ATR | 0.8861 |
| Shares Float | 68.09M |
| Short Float | 9.08% |
| Short Ratio | 7.13 |
| Volatility | 1.14 |
| Rel Volume | 0.60 |
Performance History
| Week | -4.34% |
| Month | -12.93% |
| Quarter | -0.17% |
| 6 Months | -8.31% |
| YTD | -9.69% |
| Year | +97.05% |
| 3 Years | +192.10% |
| 5 Years | -22.95% |
| 10 Years | +84.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $24.04 | 458,160 |
| 2026-06-04 | $25.10 | 467,200 |
| 2026-06-03 | $24.35 | 802,700 |
| 2026-06-02 | $24.11 | 887,500 |
| 2026-06-01 | $24.54 | 1,910,900 |
| 2026-05-29 | $25.13 | 585,700 |
| 2026-05-28 | $25.48 | 389,900 |
| 2026-05-27 | $24.79 | 509,500 |
| 2026-05-26 | $25.40 | 1,001,900 |
| 2026-05-22 | $25.61 | 478,000 |
| 2026-05-21 | $25.11 | 618,600 |
| 2026-05-20 | $24.84 | 542,900 |
| 2026-05-19 | $24.40 | 615,300 |
| 2026-05-18 | $24.43 | 750,200 |
| 2026-05-15 | $23.93 | 640,800 |
| 2026-05-14 | $23.96 | 557,500 |
| 2026-05-13 | $24.57 | 646,800 |
| 2026-05-12 | $23.90 | 724,000 |
| 2026-05-11 | $24.03 | 1,185,200 |
| 2026-05-08 | $23.89 | 1,454,100 |
| 2026-05-07 | $26.60 | 707,900 |
| 2026-05-06 | $27.61 | 427,500 |
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
đ° Latest News
Here's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-11T12:32:53Z
A Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return Updates
Simply Wall St. âĸ 2026-05-09T21:24:23Z
Zymeworks Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T09:05:19Z
Zymeworks Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T23:05:24Z
Royalty Pharma Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T20:42:50Z
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T12:25:07Z
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-05-04T21:20:04Z
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
Simply Wall St. âĸ 2026-04-27T17:38:38Z
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
MarketBeat âĸ 2026-04-26T07:12:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $105,965,000 | $76,304,000 | $76,012,000 | $412,482,000 |
| Operating Revenue | $105,965,000 | $76,304,000 | $76,012,000 | $412,482,000 |
| Expenses | ||||
| Total Expenses | $198,500,000 | $196,121,000 | $214,019,000 | $281,996,000 |
| Other Income Expense | $-559,000 | $-16,729,000 | $-894,000 | $1,110,000 |
| Other Non Operating Income Expenses | $51,000 | $-218,000 | $291,000 | $-42,000 |
| Net Non Operating Interest Income Expense | $13,354,000 | $19,941,000 | $19,705,000 | $3,596,000 |
| Operating Expense | $198,500,000 | $196,121,000 | $214,019,000 | $281,996,000 |
| General And Administrative Expense | $61,500,000 | $61,500,000 | $70,400,000 | $73,400,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Net Interest Income | $13,354,000 | $19,941,000 | $19,705,000 | $3,596,000 |
| Interest Income | $13,354,000 | $19,941,000 | $19,705,000 | $3,596,000 |
| Normalized Income | $-80,648,100 | $-109,651,310 | $-117,494,645 | $123,281,793 |
| Net Income From Continuing And Discontinued Operation | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Total Operating Income As Reported | $-92,549,000 | $-137,110,000 | $-138,053,000 | $130,528,000 |
| Average Dilution Earnings | $-196,000 | $140,000 | $0 | $-231,000 |
| Net Income Common Stockholders | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Net Income | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Net Income Including Noncontrolling Interests | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Net Income Continuous Operations | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Pretax Income | $-79,754,000 | $-116,611,000 | $-119,242,000 | $135,234,000 |
| Special Income Charges | $0 | $-17,287,000 | $0 | $0 |
| Interest Income Non Operating | $13,354,000 | $19,941,000 | $19,705,000 | $3,596,000 |
| Operating Income | $-92,535,000 | $-119,817,000 | $-138,007,000 | $130,486,000 |
| Per Share | ||||
| Diluted EPS | $-1.08 | $-1.62 | $-1.72 | $1.90 |
| Basic EPS | $-1.08 | $-1.62 | $-1.72 | $1.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $-128,100 | $-3,467,310 | $-5,645 | $92,793 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-80,815,000 | $-92,113,000 | $-119,517,000 | $141,338,000 |
| Total Unusual Items | $-610,000 | $-16,511,000 | $-1,185,000 | $1,152,000 |
| Total Unusual Items Excluding Goodwill | $-610,000 | $-16,511,000 | $-1,185,000 | $1,152,000 |
| Reconciled Depreciation | $11,110,000 | $11,193,000 | $17,305,000 | $12,004,000 |
| EBITDA (Bullshit earnings) | $-81,425,000 | $-108,624,000 | $-120,702,000 | $142,490,000 |
| EBIT | $-92,535,000 | $-119,817,000 | $-138,007,000 | $130,486,000 |
| Diluted Average Shares | $75,413,396 | $75,878,738 | $68,863,010 | $65,249,184 |
| Basic Average Shares | $75,404,897 | $75,846,681 | $68,863,010 | $65,194,775 |
| Diluted NI Availto Com Stockholders | $-81,326,000 | $-122,555,000 | $-118,674,000 | $124,110,000 |
| Tax Provision | $1,376,000 | $6,084,000 | $-568,000 | $10,893,000 |
| Impairment Of Capital Assets | $0 | $17,287,000 | $0 | $0 |
| Gain On Sale Of Security | $-610,000 | $776,000 | $-1,185,000 | $1,152,000 |
| Research And Development | $137,000,000 | $134,621,000 | $143,619,000 | $208,596,000 |
| Selling General And Administration | $61,500,000 | $61,500,000 | $70,400,000 | $73,400,000 |
| Other Gand A | $30,600,000 | $35,400,000 | $48,100,000 | $49,600,000 |
| Salaries And Wages | $30,900,000 | $26,100,000 | $22,300,000 | $23,800,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $231,000 |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $255,135,000 | $322,176,000 | $427,506,000 | $454,557,000 |
| Total Assets | $346,527,000 | $463,091,000 | $580,880,000 | $648,725,000 |
| Total Non Current Assets | $97,760,000 | $162,640,000 | $167,954,000 | $104,019,000 |
| Other Non Current Assets | $6,674,000 | $8,919,000 | $7,566,000 | - |
| Non Current Deferred Assets | $4,707,000 | $4,385,000 | $3,615,000 | $1,355,000 |
| Non Current Deferred Taxes Assets | $4,707,000 | $4,385,000 | $3,615,000 | $1,345,000 |
| Goodwill And Other Intangible Assets | $13,366,000 | $16,592,000 | $37,300,000 | $38,399,000 |
| Other Intangible Assets | $1,350,000 | $4,576,000 | $25,284,000 | $26,383,000 |
| Current Assets | $248,767,000 | $300,451,000 | $412,926,000 | $544,706,000 |
| Other Current Assets | $15,332,000 | $18,860,000 | $19,122,000 | $19,074,000 |
| Receivables | $4,638,000 | $55,815,000 | $19,477,000 | $33,400,000 |
| Accounts Receivable | $4,638,000 | $55,815,000 | $19,477,000 | $33,400,000 |
| Cash Cash Equivalents And Short Term Investments | $228,797,000 | $225,776,000 | $374,327,000 | $492,232,000 |
| Cash And Cash Equivalents | $41,157,000 | $66,103,000 | $157,557,000 | $400,912,000 |
| Cash Equivalents | $32,189,000 | $31,483,000 | - | - |
| Cash Financial | $8,968,000 | $34,620,000 | - | - |
| Non Current Prepaid Assets | - | - | $7,240,000 | $15,729,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $18,267,000 | $18,506,000 | $26,722,000 | $28,113,000 |
| Long Term Debt And Capital Lease Obligation | $14,796,000 | $15,766,000 | $22,461,000 | $24,791,000 |
| Current Debt And Capital Lease Obligation | $3,471,000 | $2,740,000 | $4,261,000 | $3,322,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $78,026,000 | $124,323,000 | $116,074,000 | $155,769,000 |
| Total Non Current Liabilities Net Minority Interest | $35,708,000 | $36,029,000 | $60,311,000 | $60,144,000 |
| Other Non Current Liabilities | $278,000 | $895,000 | $1,609,000 | $2,977,000 |
| Non Current Deferred Liabilities | $20,634,000 | $19,368,000 | $36,241,000 | $32,376,000 |
| Non Current Deferred Taxes Liabilities | $6,028,000 | $4,761,000 | $3,300,000 | $1,788,000 |
| Current Liabilities | $42,318,000 | $88,294,000 | $55,763,000 | $95,625,000 |
| Other Current Liabilities | $844,000 | $1,264,000 | $2,530,000 | $1,642,000 |
| Current Deferred Liabilities | $2,418,000 | $25,588,000 | $3,699,000 | $2,353,000 |
| Payables And Accrued Expenses | $26,757,000 | $52,480,000 | $39,120,000 | $73,943,000 |
| Payables | $4,911,000 | $5,281,000 | $8,023,000 | $26,786,000 |
| Total Tax Payable | $508,000 | $1,378,000 | $1,811,000 | $17,084,000 |
| Income Tax Payable | $83,000 | $128,000 | $1,811,000 | $840,000 |
| Accounts Payable | $4,403,000 | $3,903,000 | $6,212,000 | $7,863,000 |
| Other Payable | - | - | $729,000 | $1,839,000 |
| Equity | ||||
| Common Stock Equity | $268,501,000 | $338,768,000 | $464,806,000 | $492,956,000 |
| Total Equity Gross Minority Interest | $268,501,000 | $338,768,000 | $464,806,000 | $492,956,000 |
| Stockholders Equity | $268,501,000 | $338,768,000 | $464,806,000 | $492,956,000 |
| Gains Losses Not Affecting Retained Earnings | $-6,079,000 | $-6,952,000 | $-6,603,000 | $-6,659,000 |
| Other Equity Adjustments | $-6,079,000 | $-6,952,000 | $-6,603,000 | $-6,659,000 |
| Retained Earnings | $-953,160,000 | $-830,335,000 | $-677,437,000 | $-558,763,000 |
| Other | ||||
| Ordinary Shares Number | $75,191,597 | $68,964,319 | $70,115,997 | $63,059,501 |
| Share Issued | $75,191,597 | $68,964,319 | $70,115,997 | $63,059,501 |
| Tangible Book Value | $255,135,000 | $322,176,000 | $427,506,000 | $454,557,000 |
| Invested Capital | $268,501,000 | $338,768,000 | $464,806,000 | $492,956,000 |
| Working Capital | $206,449,000 | $212,157,000 | $357,163,000 | $449,081,000 |
| Capital Lease Obligations | $18,267,000 | $18,506,000 | $26,722,000 | $28,113,000 |
| Total Capitalization | $268,501,000 | $338,768,000 | $464,806,000 | $492,956,000 |
| Additional Paid In Capital | $114,626,000 | $152,249,000 | $142,274,000 | $151,614,000 |
| Capital Stock | $1,113,114,000 | $1,023,806,000 | $1,006,572,000 | $906,764,000 |
| Common Stock | $1,113,114,000 | $1,023,806,000 | $1,006,572,000 | $906,764,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $14,606,000 | $14,607,000 | $32,941,000 | $30,588,000 |
| Long Term Capital Lease Obligation | $14,796,000 | $15,766,000 | $22,461,000 | $24,791,000 |
| Current Deferred Revenue | $2,418,000 | $25,588,000 | $3,699,000 | $2,353,000 |
| Current Capital Lease Obligation | $3,471,000 | $2,740,000 | $4,261,000 | $3,322,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,828,000 | $6,222,000 | $6,153,000 | $14,365,000 |
| Current Accrued Expenses | $21,846,000 | $47,199,000 | $31,097,000 | $47,157,000 |
| Investments And Advances | $41,787,000 | $98,428,000 | $81,930,000 | $886,000 |
| Goodwill | $12,016,000 | $12,016,000 | $12,016,000 | $12,016,000 |
| Net PPE | $31,226,000 | $34,316,000 | $37,543,000 | $47,650,000 |
| Accumulated Depreciation | $-20,876,000 | $-17,830,000 | $-20,656,000 | $-13,299,000 |
| Gross PPE | $52,102,000 | $52,146,000 | $58,199,000 | $60,949,000 |
| Leases | $15,243,000 | $15,190,000 | $20,992,000 | $20,960,000 |
| Construction In Progress | $540,000 | $0 | $122,000 | $76,000 |
| Other Properties | $29,562,000 | $29,997,000 | $29,503,000 | $32,635,000 |
| Machinery Furniture Equipment | $6,757,000 | $6,959,000 | $7,582,000 | $7,278,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $187,640,000 | $159,673,000 | $216,770,000 | $91,320,000 |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-35,357,000 | $-113,124,000 | $-122,401,000 | $130,984,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-33,005,000 | $-110,058,000 | $-118,324,000 | $144,109,000 |
| Cash Flow From Continuing Operating Activities | $-33,005,000 | $-110,058,000 | $-118,324,000 | $144,109,000 |
| Operating Gains Losses | $532,000 | $-1,481,000 | $-31,000 | $-1,956,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,352,000 | $-3,066,000 | $-4,077,000 | $-13,125,000 |
| Investing Cash Flow | $26,663,000 | $38,756,000 | $-207,253,000 | $-53,849,000 |
| Cash Flow From Continuing Investing Activities | $26,663,000 | $38,756,000 | $-207,253,000 | $-53,849,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-41,695,000 | $-30,051,000 | $0 | $0 |
| Issuance Of Capital Stock | $4,988,000 | $0 | $76,095,000 | $107,534,000 |
| Financing Cash Flow | $-18,559,000 | $-20,438,000 | $81,868,000 | $108,582,000 |
| Cash Flow From Continuing Financing Activities | $-18,559,000 | $-20,438,000 | $81,868,000 | $108,582,000 |
| Net Other Financing Charges | $-181,000 | $-174,000 | $-53,000 | $-596,000 |
| Net Common Stock Issuance | $-36,707,000 | $-30,051,000 | $76,095,000 | $107,534,000 |
| Common Stock Issuance | $4,988,000 | $0 | $76,095,000 | $107,534,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,350,000 | $3,179,000 | $165,000 | $10,000,000 |
| End Cash Position | $41,157,000 | $66,103,000 | $157,557,000 | $400,912,000 |
| Beginning Cash Position | $66,103,000 | $157,557,000 | $400,912,000 | $201,867,000 |
| Effect Of Exchange Rate Changes | $-45,000 | $286,000 | $354,000 | $203,000 |
| Changes In Cash | $-24,901,000 | $-91,740,000 | $-243,709,000 | $198,842,000 |
| Proceeds From Stock Option Exercised | $18,329,000 | $9,787,000 | $5,826,000 | $1,658,000 |
| Common Stock Payments | $-41,695,000 | $-30,051,000 | $0 | $0 |
| Net Investment Purchase And Sale | $29,015,000 | $41,822,000 | $-203,176,000 | $-40,724,000 |
| Sale Of Investment | $225,076,000 | $325,565,000 | $350,073,000 | $72,281,000 |
| Purchase Of Investment | $-196,061,000 | $-283,743,000 | $-553,249,000 | $-113,005,000 |
| Net Intangibles Purchase And Sale | $-831,000 | $-1,075,000 | $-1,603,000 | $-4,975,000 |
| Purchase Of Intangibles | $-831,000 | $-1,075,000 | $-1,603,000 | $-4,975,000 |
| Net PPE Purchase And Sale | $-1,521,000 | $-1,991,000 | $-2,474,000 | $-8,150,000 |
| Purchase Of PPE | $-1,521,000 | $-1,991,000 | $-2,474,000 | $-8,150,000 |
| Change In Working Capital | $7,504,000 | $-30,967,000 | $-25,566,000 | $4,015,000 |
| Change In Other Working Capital | $-23,170,000 | $3,555,000 | $3,699,000 | - |
| Change In Other Current Liabilities | $-3,342,000 | $-8,313,000 | $-3,663,000 | $-3,736,000 |
| Change In Payables And Accrued Expense | $-23,693,000 | $12,639,000 | $-43,819,000 | $27,319,000 |
| Change In Payable | $-23,693,000 | $12,639,000 | $-43,819,000 | $27,319,000 |
| Change In Account Payable | $-23,648,000 | $14,321,000 | $-44,789,000 | $26,479,000 |
| Change In Tax Payable | $-45,000 | $-1,682,000 | $970,000 | $840,000 |
| Change In Income Tax Payable | $-45,000 | $-1,682,000 | $970,000 | $840,000 |
| Change In Prepaid Assets | $6,509,000 | $-2,489,000 | $4,295,000 | $-2,059,000 |
| Change In Receivables | $51,200,000 | $-36,359,000 | $13,922,000 | $-17,509,000 |
| Changes In Account Receivables | $51,200,000 | $-36,359,000 | $13,922,000 | $-17,509,000 |
| Stock Based Compensation | $28,034,000 | $17,792,000 | $8,102,000 | $4,015,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $667,000 | $0 |
| Asset Impairment Charge | $0 | $17,287,000 | $0 | $0 |
| Deferred Tax | $945,000 | $691,000 | $-757,000 | $1,940,000 |
| Deferred Income Tax | $945,000 | $691,000 | $-757,000 | $1,940,000 |
| Depreciation Amortization Depletion | $11,110,000 | $11,193,000 | $17,305,000 | $12,004,000 |
| Depreciation And Amortization | $11,110,000 | $11,193,000 | $17,305,000 | $12,004,000 |
| Amortization Cash Flow | $4,056,000 | $4,496,000 | $2,702,000 | $1,015,000 |
| Amortization Of Intangibles | $4,056,000 | $4,496,000 | $2,702,000 | $1,015,000 |
| Depreciation | $7,054,000 | $6,697,000 | $14,603,000 | $10,989,000 |
| Net Foreign Currency Exchange Gain Loss | $532,000 | $-1,481,000 | $-31,000 | $-1,956,000 |
| Net Income From Continuing Operations | $-81,130,000 | $-122,695,000 | $-118,674,000 | $124,341,000 |
| Repayment Of Debt | - | $-14,000 | $-21,000 | $-14,000 |
| Net Issuance Payments Of Debt | - | $-14,000 | $-21,000 | $-14,000 |
| Net Long Term Debt Issuance | - | $-14,000 | $-21,000 | $-14,000 |
| Long Term Debt Payments | - | $-14,000 | $-21,000 | $-14,000 |
| Other Non Cash Items | - | $-1,878,000 | $630,000 | $-250,000 |
Fetched: 2026-05-23